← Back to Search

Anticoagulant

Apixaban for Deep Vein Thrombosis (CARAVAGGIO Trial)

Phase 3
Waitlist Available
Research Sponsored by Fadoi Foundation, Italy
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

CARAVAGGIO Trial Summary

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study

Eligible Conditions
  • Deep Vein Thrombosis

CARAVAGGIO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrent venous thromboembolism

Side effects data

From 2018 Phase 4 trial • 557 Patients • NCT01884337
7%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)

CARAVAGGIO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ApixabanExperimental Treatment1 Intervention
orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
Group II: DalteparinActive Control1 Intervention
subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban
FDA approved

Find a Location

Who is running the clinical trial?

Fadoi Foundation, ItalyLead Sponsor
15 Previous Clinical Trials
17,302 Total Patients Enrolled
University Of PerugiaOTHER
73 Previous Clinical Trials
81,593 Total Patients Enrolled
3 Trials studying Deep Vein Thrombosis
1,443 Patients Enrolled for Deep Vein Thrombosis
University of Perugia, ItalyUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
2017. "Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03045406.
All > Eliquis > Apixaban
~146 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top